Home LiteratureArticle Details
PMID: 6595963 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Multiple-dose pharmacokinetics of imipenem-cilastatin.

Antimicrobial agents and chemotherapy ·Vol. 26 ·No. 5 ·1984-11-00 ·Pages 715-21

Drusano GL, Standiford HC, Bustamante C, Forrest A, Rivera G, Leslie J, Tatem B, Delaportas D, MacGregor RR, Schimpff SC

Abstract

We characterized the pharmacokinetic profile of imipenem-cilastatin administered intravenously to six normal volunteers in a dose of 1,000 mg of each drug every 6 h for 40 doses. The plasma concentrations of imipenem and cilastatin 1 h after the end of a 30-min infusion were 18.7 (+/- 2.1) and 19.1 (+/- 4.6), 20.0 (+/- 3.2) and 17.8 (+/- 4.8), and 23.4 (+/- 2.3) and 19.1 (+/- 3.5) micrograms/ml in the 1st, 17th, and 37th dosing intervals, respectively. The central compartment volumes of distribution for imipenem and cilastatin were 0.16 (+/- 0.05) and 0.14 (+/- 0.03) liter/kg, respectively. Elimination half-lives were short: 0.93 (+/- 0.09) h for imipenem and 0.84 (+/- 0.11) h for cilastatin. Plasma clearances were 12.1 (+/- 0.06) liters/h per 1.73 m2 for imipenem and 12.4 (+/- 1.1) liters/h per 1.73 m2 for cilastatin. Renal clearance accounted for 54% of the plasma clearance of imipenem and 69% of the plasma clearance of cilastatin. The concentrations of imipenem in plasma and urine remained above the MICs of the vast majority of pathogens throughout the dosing interval.

MeSH Terms
Adult Anti-Bacterial Agents/metabolism Cilastatin Cyclopropanes/metabolism,urine Drug Administration Schedule Drug Combinations Half-Life Humans Imipenem Injections, Intravenous Kinetics Male Thienamycins/metabolism,urine
Chemicals
Anti-Bacterial Agents Cyclopropanes Drug Combinations Thienamycins Cilastatin Imipenem
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Drusano G L
Standiford H C
Bustamante C
Forrest A
Rivera G
Leslie J
Tatem B
Delaportas D
MacGregor R R
Schimpff S C
References (9)
9 references, click to expand
  1. A program package for simulation and parameter estimation in pharmacokinetic systems.
    Comput Programs Biomed. 1979 Mar;9(2):115-34 PMID: 761456
  2. In vitro activity of N-formimidoyl thienamycin (MK0787).
    Antimicrob Agents Chemother. 1980 Oct;18(4):642-4 PMID: 6934708
  3. In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp.
    Antimicrob Agents Chemother. 1981 Jan;19(1):114-6 PMID: 6787975
  4. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Antimicrob Agents Chemother. 1981 Feb;19(2):248-52 PMID: 6214986
  5. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers.
    Antimicrob Agents Chemother. 1984 Nov;26(5):707-14 PMID: 6595962
  6. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.
    Antimicrob Agents Chemother. 1983 Feb;23(2):293-9 PMID: 6573156
  7. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.
    Antimicrob Agents Chemother. 1983 Feb;23(2):300-7 PMID: 6573157
  8. Thienamycin: development of imipenen-cilastatin.
    J Antimicrob Chemother. 1983 Dec;12 Suppl D:1-35 PMID: 6365872
  9. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.
    Antimicrob Agents Chemother. 1982 Jul;22(1):62-70 PMID: 7125632
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1984-11-00
Pages
715-21
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC180001
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com